Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
NCT06444165
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
55
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Lebrikizumab Pen
Sponsor
Eli Lilly and Company